2021
DOI: 10.1016/j.coph.2021.09.002
|View full text |Cite
|
Sign up to set email alerts
|

New trends in pharmacological control of neuropsychiatric symptoms of dementia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
5
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
8

Relationship

4
4

Authors

Journals

citations
Cited by 8 publications
(5 citation statements)
references
References 48 publications
0
5
0
Order By: Relevance
“…This is fundamental since the glutamatergic [24,25] and serotonergic [26] mechanisms are significantly involved in aging and neurodegeneration and, thus, they are also involved in the mechanism of action of rapid acting antidepressants [27]. This finding could break new ground for the treatment of neuropsychiatric symptoms [28]. This deepening of the characterization of the neuropharmacological profile of BEO is fundamental to elucidate all of its properties since BEO may provide an effective option for the management of agitation that is closely connected to under-treated pain [29] and, unfortunately, that is managed with antipsychotics, doubling the risk of death caused by cardiocerebrovascular accidents in the elderly [30], something that is even more relevant during the pandemic [31].…”
Section: Discussionmentioning
confidence: 99%
“…This is fundamental since the glutamatergic [24,25] and serotonergic [26] mechanisms are significantly involved in aging and neurodegeneration and, thus, they are also involved in the mechanism of action of rapid acting antidepressants [27]. This finding could break new ground for the treatment of neuropsychiatric symptoms [28]. This deepening of the characterization of the neuropharmacological profile of BEO is fundamental to elucidate all of its properties since BEO may provide an effective option for the management of agitation that is closely connected to under-treated pain [29] and, unfortunately, that is managed with antipsychotics, doubling the risk of death caused by cardiocerebrovascular accidents in the elderly [30], something that is even more relevant during the pandemic [31].…”
Section: Discussionmentioning
confidence: 99%
“…Another important feature of the pharmacological activity of BEO for clinical use is its lack of sedative effects (that could increase cognitive deterioration), supported by the involvement of serotonergic neurotransmission [ 49 ]. This neuromodulation is a fundamental target during aging and neurodegeneration [ 50 ], as demonstrated by the action of rapid-acting antidepressants [ 51 ], which could represent a revolutionary therapy for the neuropsychiatric symptoms [ 52 ]. Therefore, the deep characterization of the analgesic properties of BEO, as well as of its fractions and components, via the transdermal route is fundamental since its engineered nanotechnological delivery system, NanoBEO, is administered via the same route and is the soundest candidate essential oil for investigation in the clinical management of pain and agitation.…”
Section: Discussionmentioning
confidence: 99%
“…The studies found by the present search of databases and inspection of references in the literature demonstrate a main effect of essential oils on general well-being and sleep. However, these symptoms and the benefits of them might be linked to pain processing [ 86 ], although not always being detected by an appropriate measure tool, mainly in older patients and in the case of depression [ 87 ]. This is supported by meta-analysis that demonstrates the effectiveness of essential oils used as aromatherapy in the reduction of the intensity of cancer-related pain, assessed through unidimensional pain scales ( p = 0.002).…”
Section: Discussionmentioning
confidence: 99%